World's Best Scientists 2026 revealed!
Cora N. Sternberg

Cora N. Sternberg

Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
120
Citations
79337
World Ranking
544
National Ranking
325

Medicine

D-Index
121
Citations
84976
World Ranking
3533
National Ranking
1944

Cora N. Sternberg publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Cora N. Sternberg sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 905 publications — 92nd percentile

92% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Cora N. Sternberg D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Cora N. Sternberg sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 121 D-Index — 83rd percentile

83% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Cora N. Sternberg is affiliated with Cornell University in the United States and is an active contributor to medical research, primarily within the field of Medicine. Their scientific work emphasizes oncology with significant involvement in pulmonary and respiratory medicine, surgery, cancer research, radiology, nuclear medicine, and imaging. The subfields align closely with their main research focus on cancer and related treatments.

Their publication record features several recent papers spanning advanced cancer therapies and clinical oncology. Notable publications include:

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma, 2020, New England Journal of Medicine
  • Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration, 2020, Journal of Clinical Oncology
  • TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors, 2021, Journal of Clinical Oncology
  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, 2020, New England Journal of Medicine
  • Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial, 2021, The Lancet Oncology

The scope of research touches on key topics such as:

  • Prostate Cancer Treatment and Research
  • Bladder and Urothelial Cancer Treatments
  • Cancer Immunotherapy and Biomarkers
  • Radiopharmaceutical Chemistry and Applications
  • Urinary and Genital Oncology Studies
  • Cancer, Lipids, and Metabolism
  • Renal Cell Carcinoma Treatment

Frequent coauthors contributing alongside Sternberg include Scott T. Tagawa, David M. Nanus, Ana M. Molina, Karim Fizazi, and Yohann Loriot, indicating collaborative contributions within the oncology research community.

Their publications are primarily found in journals with a strong clinical oncology and cancer focus, such as:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Bladder Cancer
  • European Urology
  • The Journal of Urology

Best Publications

  • Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

    Howard I. Scher;Karim Fizazi;Fred Saad;Mary-Ellen Taplin

  • Abiraterone and Increased Survival in Metastatic Prostate Cancer

    Johann S. de Bono;Christopher J. Logothetis;Arturo Molina;Karim Fizazi

  • Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

    Tomasz M Beer;Andrew J Armstrong;Dana E Rathkopf;Yohann Loriot

  • Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

    Joaquim Bellmunt;Ronald De Wit;David J. Vaughn;Yves Fradet

  • Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

    Cora N. Sternberg;Ian D. Davis;Jozef Mardiak;Cezary Szczylik

  • Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

    Michel Bolla;Laurence Collette;Léo Blank;Padraig Warde

  • Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;David Cella;James Reeves

  • Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

    Howard I. Scher;Susan Halabi;Ian Tannock;Michael Morris

  • Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

    Michel Bolla;Dionisio Gonzalez;Padraig Warde;Jean Bernard Dubois

  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

    Howard I. Scher;Michael J. Morris;Walter M. Stadler;Celestia Higano

  • Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial

    Andrea Wang-Gillam;Chung-Pin Li;György Bodoky;Andrew Dean

  • Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

    Karim Fizazi;Howard I. Scher;Arturo Molina;Christopher J. Logothetis

  • Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the Urothelium

    J.L. Gabrilove;J.L. Gabrilove;A. Jakubowski;A. Jakubowski;H. Scher;H. Scher;C. Sternberg;C. Sternberg

  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study

    Charles J. Ryan;Matthew R. Smith;Karim Fizazi;Fred Saad

  • Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma

    Thomas Powles;Se Hoon Park;Eric Voog;Claudia Caserta

  • External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study

    Michel Bolla;Geertjan Van Tienhoven;Padraig Warde;Jean Bernard Dubois

  • Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer

    Maha Hussain;Karim Fizazi;Fred Saad;Per Rathenborg

  • Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial

    Toni K Choueiri;Bernard Escudier;Thomas Powles;Nizar M Tannir

  • Preliminary Results of M-VAC (Methotrexate, Vinblastine, Doxorubicin and Cisplatin) for Transitional Cell Carcinoma of the Urothelium

    Cora N. Sternberg;Cora N. Sternberg;Cora N. Sternberg;Alan Yagoda;Alan Yagoda;Alan Yagoda;Howard I. Scher;Howard I. Scher;Howard I. Scher;Robin C. Watson;Robin C. Watson;Robin C. Watson

  • Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

    Michel Bolla;Hein van Poppel;Bertrand Tombal;Kris Vekemans

Frequent Co-Authors

Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
Fred Saad
Fred Saad University of Montreal
Karim Fizazi
Karim Fizazi University of Paris-Saclay
Howard I. Scher
Howard I. Scher Memorial Sloan Kettering Cancer Center
Bertrand Tombal
Bertrand Tombal Université Catholique de Louvain
Thomas Powles
Thomas Powles Queen Mary University of London
Johann S. de Bono
Johann S. de Bono Institute of Cancer Research
Toni K. Choueiri
Toni K. Choueiri Harvard University
Celestia S. Higano
Celestia S. Higano University of Washington
Tomasz M. Beer
Tomasz M. Beer Oregon Health & Science University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re exploring medicine in the USA, there are diverse online nursing and healthcare programs to consider. Many students look at how much does online nursing school cost as affordability is a critical factor. Accredited online nursing programs can offer flexibility and reduced expenses compared to traditional on-campus options.

For those already holding an RN license, advancing your qualifications can be quicker and more affordable with the cheapest rn to bsn program choices. These programs help RNs transition to a BSN for higher earning potential and expanded career paths.

If your career goals include leadership roles or research, pursuing an advanced degree like an online phd in nursing can open new doors. These programs are designed for nurses aiming to reach the highest levels of expertise, often at a more manageable cost thanks to online options.

Even if you come from a non-nursing background, options such as online direct entry msn programs for non-nursing majors can fast-track your entry into the nursing profession. These programs provide an accelerated pathway, making a healthcare career more accessible than ever.

Best Scientists Citing Cora N. Sternberg

Trending Scientists